Venture Life Share Discussion Threads

[qs99] 19/4/2024 07:22

Cracking update IMO

[rivaldo] 19/4/2024 07:13

Good to see the new RCF now agreed - and also:

"New Partner in USA

The Company also announces that it has finalised an exclusive long-term license and distribution deal in the United States for Gelclair, an FDA-approved oral mucositis prescription product, with Jaguar Health (NASDAQ:JAGX). This agreement, spanning 5 years, entails license fees, royalties, and product revenue payments to the Company.

"We are really pleased to have partnered Gelclair in the USA, a market where Gelclair has been present for many years," said Jerry Randall, CEO of VLG. "This new agreement will ensure the continued supply of Gelclair to US oncology patients suffering oral mucositis, and generate meaningful additional revenues for the Company in the future."

[celeritas] 12/4/2024 15:28

I've added a good few today... Stock is very tight.

[lammylover] 12/4/2024 15:25

Some decent volume gone through the last 2 days - hopefully those sellers who only want 37-38p for their shares will soon be out and new money will enter to take this forward..

[bagpuss67] 12/4/2024 08:29

A bit disappointed with the reaction to the results. Lets hope that people keep accumulating and we see a continuation of the upwards share price trend

[deanowls] 09/4/2024 19:04

With more of thier own brands the rating should be higher but the questions are how safe is the 27m of other brands that they contract manufacture for? They had to cut 400k to retain a contract.

Within the next six months it may pay to get another brand in if it’s a good deal. The more of thier own brands they have the more in control they are. Upgs have done the same.

[lammylover] 09/4/2024 18:44

Just covered in Investors Chronicle by Simon Thompson:

He concludes:
For the year ahead, house broker Cavendish expects adjusted operating profit margins to increase one percentage point to 8.5 per cent, which on 7 per cent higher revenue of £55mn could drive up operating profit 20 per cent to £4.7mn. Furthermore, estimated free cash flow of £6.1mn (2024) and £7.8mn (2025) is predicted to slash net debt from £13.7mn to £9.2mn (2024) and £1.9mn (2025). In other words, the £47mn market capitalisation company is on course to be almost debt free next year when it is forecast to deliver underlying operating profit of £6.1mn on revenue of £59.4mn.

The operational improvement in the business and balance sheet deleveraging were key bull points when I suggested buying the shares, at 30.5p (‘Investors are too cautious with this cash-generative company’, 26 September 2023). That’s still the case. Cavendish’s fair valuation of 68p a share is not unreasonable, representing a target forward price/earnings (PE) ratio of 10 for 2025. Buy.

[rimau1] 09/4/2024 17:39

Cavendish’s fair valuation of 68p, representing a target forward price/earnings (PE) ratio of 10 for 2025.
I personally think Cavendish are too cautious on revenue and margins. For the year ahead Cavendish expects adjusted operating profit margins to increase one percentage point to 8.5 per cent, which on 7 per cent higher revenue of £55mn could drive up operating profit 20 per cent to £4.7mn. FCF of £6.1mn (2024) and £7.8mn (2025) reduces net debt from £13.7mn to £9.2mn (2024) and £1.9mn (2025). So on course to be almost debt free next year when it is forecast to deliver underlying operating profit of £6.1mn on revenue of £59.4mn.

[wjccghcc] 09/4/2024 16:37

Cavendish downgrade FY24 EPS forecast to 5.5p from 6.4p. Puts them on a PE of 7 for 4% earnings growth.

[celeritas] 09/4/2024 11:25

This is such a cheap target. A great set of numbers will have others pondering I'm sure.

[basem1] 09/4/2024 08:31

Finger on the buy button I derisked 70,000 yesterday at 38.9 but still have 95000 Happy to buy back at 37 or below

[rivaldo] 09/4/2024 08:29

The MMs actually marked the price up, but I suspect as usual short-term traders who shifted the price up pre-results are now exiting with their profits (or losses).

Now off to read the broker note....

[qs99] 09/4/2024 08:24

Thanks Brummy, especially your opening few paras, wonder therefore if VC world will hoover VLG up in 2024 then?

market marked VLG down on these results, perhaps management will want to take it private?

DYOR

[1jat] 09/4/2024 08:21

Looking forward to the investor meets company call on Thursday.

Like the sales progress and product enhancements…..but will there be a game changer here or just more of the same?

I dont like the level of adjustments between the final results and the AOP and AEBITDA.

[brummy_git] 09/4/2024 08:19

In this upbeat interview, CEO Jerry Randall of consumer healthcare products firm Venture Life takes me through today's in line yearend trading update & positive outlook for 2024.

[bagpuss67] 09/4/2024 08:04

Muted response.

[brummy_git] 09/4/2024 07:56

Commentary wrt today's in line FY23 & positive outlook

[pedigree_scum] 09/4/2024 07:42

Great set of results. Onwards and upwards

[rivaldo] 09/4/2024 07:42

Certainly reads well on first look, with 5.21p adjusted EPS, net debt falling nicely, selling prices across key VLG brands in UK retail increased by almost 10% this year and a very bullish outlook:

"I am delighted to announce another successful year for Venture Life Group, marked by significant commercial achievements and strengthened financial positions. Our strategic emphasis on organic growth and cash generation led to a faster reduction in net debt despite challenging market conditions. We have made notable inroads in new product development, resulting in increased revenue and showcasing our innovative in-house R&D capabilities. Furthermore, enhanced branding and marketing efforts have expanded the reach of our 9 key brands to a broader global audience, further propelling our growth trajectory. With a strong commitment to improving EBITDA margins, successful new product launches, and digital transformation initiatives, we are well-positioned for sustained success in 2024 and beyond."

[thedudie] 08/4/2024 11:51

Yes.
Hopefully they also give an update on the first 3 months of 2024. They implied license wins and deals along with price rises had come through late in 2023 suggesting I think that they were presumably too late to impact.
Hopefully the current trading outlook can show significant growth.

[qs99] 08/4/2024 11:41

Nice moves ahead of the results ....DYOR

[celeritas] 05/4/2024 15:37

There's just so many markets to go at for VLG with their products. Debrox sold 4.1m units in the US and that contains Carbamide Peroxide, certainly not something I would stick in my ear... Balance activ has got huge markets to go at, feminine hygiene is worth nearly $5billion in the US alone.
Its worth $1.6billion in Brazil, a market they have started to enter..

Our UK market is worth $780m for feminine hygiene, so it shows you what they have to go at.

[eagle eye] 05/4/2024 10:41

Full Year results will be released on Tuesday 9th April.
Should make interesting reading, especially with the recent positive trading update.